Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

Company Overview - Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [2] - The company markets three main products in the United States: MACI, Epicel, and holds an exclusive license for NexoBrid [2] Product Details - MACI is an autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee, applicable to adults [2] - Epicel is a permanent skin replacement for treating patients with deep dermal or full-thickness burns covering 30% or more of total body surface area [2] - NexoBrid is a biological orphan product indicated for eschar removal in patients with deep partial-thickness and/or full-thickness burns [2] Upcoming Events - Vericel Corporation will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4, 2025, at 3:45 p.m. ET, with a webcast available on their Investor Relations website [1]